News – Multitude Therapeutics

Skip to content

News

Multitude Therapeutics’ AMT-676 Receives Breakthrough Therapy Designation from China’s CDE

2026-08-05

On June 26, 20…
Read More →
U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253

2026-08-04

On July 24, 20…
Read More →
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress

2026-07-02

AMT-676 is a p…
Read More →
Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors

2026-07-02

Download Full …
Read More →
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation

2025-12-17

December 17, 2…
Read More →
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

2025-10-19

Multitude Ther…
Read More →
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

2025-10-17

Multitude Ther…
Read More →